Recombinant TPP1 (cerliponase alfa) was approved for treatment of the brain in CLN2 disease, an inherited lysosomal storage disorder, and the enzyme was infused into one lateral ventricle bimonthly via an Ommaya reservoir [110]. This evidence concerns the gene TPP1 and lysosomal storage disease.